In Vivo Drug Delivery Performance of Lipiodol-Based Emulsion or Drug-Eluting Beads in Patients with Hepatocellular Carcinoma.
作者： Elsa Lilienberg , Ilse R. Dubbelboer , Amar Karalli , Rimma Axelsson , Torkel B. Brismar
DOI: 10.1021/ACS.MOLPHARMACEUT.6B00886
关键词: Lipiodol 、 Hepatocellular carcinoma 、 Liver cancer 、 Cmax 、 Drug delivery 、 Urology 、 Doxorubicin 、 Pharmacology 、 Medicine 、 In vivo 、 Pharmacokinetics
摘要: Doxorubicin (DOX) delivered in a lipiodol-based emulsion (LIPDOX) or drug-eluting beads (DEBDOX) is used as palliative treatment patients with intermediate-stage hepatocellular carcinoma (HCC). The primary objective of this study was to evaluate the vivo delivery performance DOX from LIPDOX DEBDOX HCC using local and systemic pharmacokinetics its main metabolite doxorubicinol (DOXol). Urinary excretion DOXol their short-term safety antitumor effects were also evaluated. In open, prospective, nonrandomized multicenter study, (n = 13) 12) injected into feeding arteries tumor. Local (vena cava/hepatic vein orifice) (peripheral vein) plasma concentrations determined samples obtained up 6 h 7 days after treatment. Tumor response assessed computed tomography magnetic resonance imaging. Cmax AUC0–24 h for 5.6-fold 2.4-fold higher in...
acs.org
sci-hub.se 参考文章(49)
Onkar S. Bains, András Szeitz, Joanna M. Lubieniecka, Gina E. Cragg, Thomas A. Grigliatti, K. Wayne Riggs, Ronald E. Reid, A correlation between cytotoxicity and reductase-mediated metabolism in cell lines treated with doxorubicin and daunorubicin Journal of Pharmacology and Experimental Therapeutics. ,vol. 347, pp. 375- 387 ,(2013) , 10.1124/JPET.113.206805
Emelie Ahnfelt, Erik Sjögren, Per Hansson, Hans Lennernäs, In Vitro Release Mechanisms of Doxorubicin From a Clinical Bead Drug-Delivery System. Journal of Pharmaceutical Sciences. ,vol. 105, pp. 3387- 3398 ,(2016) , 10.1016/J.XPHS.2016.08.011
Gang Young, Charles Breedis, The blood supply of neoplasms in the liver. American Journal of Pathology. ,vol. 30, pp. 969- 977 ,(1954)
Oktay Tacar, Pornsak Sriamornsak, Crispin R. Dass, Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems Journal of Pharmacy and Pharmacology. ,vol. 65, pp. 157- 170 ,(2012) , 10.1111/J.2042-7158.2012.01567.X
Jacques Ferlay, Isabelle Soerjomataram, Rajesh Dikshit, Sultan Eser, Colin Mathers, Marise Rebelo, Donald Maxwell Parkin, David Forman, Freddie Bray, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer. ,vol. 136, ,(2015) , 10.1002/IJC.29210
Mathieu Boulin, Antonin Schmitt, Elisabeth Delhom, Jean-Pierre Cercueil, Maëva Wendremaire, Diane-Charlotte Imbs, Audrey Fohlen, Fabrizio Panaro, Astrid Herrero, Alban Denys, Boris Guiu, Improved stability of lipiodol-drug emulsion for transarterial chemoembolisation of hepatocellular carcinoma results in improved pharmacokinetic profile: Proof of concept using idarubicin. European Radiology. ,vol. 26, pp. 601- 609 ,(2016) , 10.1007/S00330-015-3855-4
Hiroshi Maeda, Yasuhiro Matsumura, EPR effect based drug design and clinical outlook for enhanced cancer chemotherapy Advanced Drug Delivery Reviews. ,vol. 63, pp. 129- 130 ,(2011) , 10.1016/J.ADDR.2010.05.001
Julien Namur, Steven J. Citron, Marty T. Sellers, Mark H. Dupuis, Michel Wassef, Michel Manfait, Alexandre Laurent, Embolization of hepatocellular carcinoma with drug-eluting beads: Doxorubicin tissue concentration and distribution in patient liver explants Journal of Hepatology. ,vol. 55, pp. 1332- 1338 ,(2011) , 10.1016/J.JHEP.2011.03.024
S Bhattacharya, AP Dhillon, MC Winslet, BR Davidson, N Shukla, SD Gupta, R AL-Mufti, KEF Hobbs, Human liver cancer cells and endothelial cells incorporate iodised oil British Journal of Cancer. ,vol. 73, pp. 877- 881 ,(1996) , 10.1038/BJC.1996.156
S. Eksborg, H. -S. Strandler, F. Edsmyr, I. N�slund, P. Tahvanainen, Pharmacokinetic study of IV infusions of adriamycin European Journal of Clinical Pharmacology. ,vol. 28, pp. 205- 212 ,(1985) , 10.1007/BF00609693